Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).

Publication

Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).

Journal Paper/Review - Jan 1, 2022

Mueller Ruediger B, Schulze-Koops Hendrik, Furst Daniel E, Cohen Stanley B, Kwok Kenneth, Wang Lisy, Killeen Tim, von Kempis Johannes

Citation

Mueller R, Schulze-Koops H, Furst D, Cohen S, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol 2022; 41:1045-1055.

Type

Journal Paper/Review (English)

Journal

Clin Rheumatol 2022; 41

Publication Date

Jan 1, 2022

Issn Electronic

1434-9949

Pages

1045-1055

Brief description/objective

We assess the impact of switching versus staying on the same tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis (RA).